Search Results for "Novasite Pharmac"
Original Source: Novasite Pharmaceuticals, Inc
Novasite is a drug discovery company using structure-function relationships in validated G protein coupled receptor targets to find better GPCR modulating drugs.Novasite began as a majority-owned subsidiary of Applied Molecular Evolution, Inc. (“AME”), which was acquired by Eli Lilly in 2004 for $400M. Novasite is the exclusive licensee of AME molecular evolution technology, which the Company adapted for the discovery and optimization of small molecule GPCR modulating drugs. Funded by $20 million in pri...
Matching Channels
None
Matching News
NZ's PHARMAC consults on funding for Iressa and Tarceva
The Pharmaceutical Management Agency of New Zealand, PHARMAC, is seeking feedback on a proposal to:
BIO Says New Zealand's Pharmac Hinders Development
The Biotechnology Industry Organization accused New Zealand's Pharmac of inhibiting pharmaceutical development in the country.
Pharmac Says 10% Of New Zealanders Prescribed Antidepressants
New Zealand's government drug purchaser, Pharmac, says 10% of the nation's population is taking prescribed antidepressants, an amount one academic psychiatrist said is excessive.
Sole-supplier contracts continue to cause controversy in New Zealand, even as PHARMAC defends the practice.
New Zealand's Pharmac Willing To Talk Price For Orphan-Hemophilia Drug
New Zealand's Pharmac said the drug-coverage agency is weighing the $421,000-a-year cost against the benefits of subsidizing Alexion's Soliris (eculizumab) in treating to a rare type of hemophilia.
New Zealand's PHARMAC to fund alternative treatments for asthma, scabies from Merck
New Zealand's Pharmaceutical Management Agency PHARMAC is to fund a treatment for pre-schoolers with recurrent wheezing despite using other therapies, and for people with exercise-induced asthma.
New Zealand’s Pharmac Drug-Buying Agency Sets Two-Tiered Funding
New Zealand’s drug-funding agency, Pharmac, has established a procedure for district health-board hospitals to standardize pharmaceutical treatments throughout the country.
New Zealand’s Pharmac Agrees To Cover Two Merck Scabies Drugs
New Zealand’s Pharmac drug purchasing has agreed to cover, almost immediately, Merck’s Singulair (montelukast) for asthmatics, including children under the age of five years who have recurrent whe...
Matching PubMed Articles
Iron overload (IO), primarily related to multiple red blood cell transfusions, is a relatively common complication in hematopoietic stem cell transplant (HSCT) recipients. Elevated pretransplant ferri...
